Home  /  Resource Library  /  Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenstrom Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenstrom Macroglobulinemia

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenstrom Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenstrom Macroglobulinemia

ASH 2024